Metabolic & Endocrine
Hypothyroidism
35
Pipeline Programs↗
13
Active Trials↗
16
Companies Involved↗
Hypothyroidism is a moderately active landscape with 35 programs across 16 companies. The most active players are AstraZeneca, Sention Therapeutics, LLC, Pascoe Pharmazeutische Praeparate GmbH. 15 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 12
Phase 25
Analysis
Trial Status
59
clinical trials
Completed28 · 47%
Unknown status12 · 20%
Recruiting9 · 15%
Withdrawn4 · 7%
Not yet recruiting3 · 5%
Terminated2 · 3%
Other1 · 2%
Clinical Trials
Trial Activity
59 trials
Periodization Resistance Training on Quality of Life in Females With Hypothyroidism
Recruiting·—·N/A·NCT06757712·75 enrolled
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Not yet recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 1·NCT06373523·60 enrolled
LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss
Not yet recruiting·WWomen's Hospital School Of Medicine Zhejiang University·Phase 3·NCT06999278·200 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)